PROVIDING VALUE-​​ADDED INNOVATIONS

Innokeys is a Singapore based biotechnology company founded in 2012 with the aim of developing and commercializing innovations that fulfill unmet medical needs in oncology.


Together with InnoCIMAB and CIMAB, Innokeys is currently coordinating the global development activities of nimotuzumab, an anti-EGFR monoclonal antibody to treat solid cancers of epithelial origin. Nimotuzumab was invented in Cuba by the Center of Molecular Immunology (CIM) and was licensed to CIMYM, a subsidiary of YM Biosciences (Canada) for early clinical development before the license was acquired by Innokeys in 2012. Late stage clinical development is now being carried out globally by various partners in different indications, including head and neck cancer, pancreatic cancer, gastric cancer, cervical cancer and others. Currently nimotuzumab is already approved in more than 30 countries world-wide.